New Patch in the pipeline of new products
Transdur-sufentanil patches, a transdermal patch for sufentanil, is in clinical trials. In 2005, a company named "Durect" entered into an agreement with Endo Pharmaceuticals granting Endo exclusive rights to develop, market and commercialize TRANSDUR-Sufentanil in the U.S. and Canada.
In 2006, Endo and Durect successfully completed the first clinical trial of the Phase II program for TRANSDUR-Sufentanil using patches manufactured by us to evaluate the transition of chronic pain patients from Duragesic to TRANSDUR-Sufentanil.
Evaluation of plasma level data indicate that TRANSDUR-Sufentanil performed as designed by achieving its target delivery profile of providing a rapid onset of drug and a delivery of very consistent blood plasma levels. The product was tolerated well with no apparent safety issues over the four-week treatment period.
For us as patients, what's really encouraging is that the patch is approximately 1/5th the size of Duragesic, and lasts for 7 days. Endo is conducting Phase II studies designed to evaluate the conversion of chronic pain patients treated with other oral opioid products to TRANSDUR-Sufentanil.
Sounds encouraging.....Another potential weapon in the fight against chronic pain!